Diagnostics firm Avacta Group names head of research and development amid expansion into antibody market.

Avacta Group, a Leeds University spin-out specialising in diagnostic tools, has named Matt Johnson as its lead affirmer of research and development and production operations as it capitalises on its Affirmers intellectual property (IP).

The firm acquired the rights to the IP in February 2012, which is an alternative to antibodies based on a robust protein scaffold. Currently, the antibody market is estimated at over $50bn, and are presently the only major class of affinity reagents despite suffering from technical…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?